High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women

AIDS

Volumn 24, Issue 15, 2010, Pages 2416-2418

  McKeown, Denise A ^a   Rosenvinge, Melanie ^b   Donaghy, Sheila ^c   Sharland, Mike ^c   Holt, David W ^a   Cormack, Ian ^d   Hay, Phillip ^a,b   Sadiq, S Tariq ^a,b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Department of GUM ^*  (United Kingdom)

^c ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d CROYDON HEALTH SERVICES NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; VIRUS DNA; ZIDOVUDINE;

ADD ON THERAPY; ADULT; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG BLOOD LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; NAUSEA; NEWBORN; PLACENTAL TRANSFER; PREGNANT WOMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; VIRUS LOAD;

ADULT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRROLIDINONES;

EID: 77957242789     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833d8a50     Document Type: Letter

References (8)

1. Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors andCCR5 antagonists. J InfectDis 2008; 57:1-10.
2. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, et al. Metabolism and disposition in humans of raltegravir (MK-0518): an anti-aids drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657-1663. (Pubitemid 47296061)
3. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update. Antiviral Res 2010; 85:176-189.
4. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 1999; 36:439-452.
5. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44:989-1008.
6. Gulatia A, Gerk PM. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. J Pharm Sci 2009; 98:2317-2335.
7. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, et al. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 2000; 279:1495-1503.
8. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the fetus. Br J Clin Pharmacol 2007; 65:667-673. (Pubitemid 351535077)